Case Report

Visceral Leishmaniasis or Systemic Lupus Erythematosus Flare?

Sunny Garg,1 Mousumi Kundu,1 Amit Nandan Dhar Dwivedi,2 Lalit Prashant Meena,1 Neeraj Varyani,1 Asif Iqbal,1 and Kamlakar Tripathi1

1 Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India
2 Department of Radiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India

Correspondence should be addressed to Sunny Garg, sunnygarg1987@gmail.com

Received 20 June 2012; Accepted 30 July 2012

Academic Editors: B. Sarov and A. Vojdani

Copyright © 2012 Sunny Garg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Systemic lupus erythematosus (SLE) is a multisystem disorder characterised by B-cell hyperactivity with production of multiple autoantibodies. Fever in SLE may be caused by disease exacerbation or by infection. We report a patient of SLE that was later complicated by fever, pancytopenia, and massive splenomegaly. Corticosteroid therapy for SLE might have masked the underlying infection at earlier stage. Despite negative results of rk-39 test and bone marrow biopsy, a very high suspicion for visceral leishmaniasis (VL) led us to go for direct agglutination test (DAT) and polymerase chain reaction (PCR) for leishmanial antigen that revealed positive results. Moreover, significant improvement in clinical and biochemical parameters was noted on starting the patient on antileishmanial therapy.

1. Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology, characterised by B-cell hyperactivity and production of multiple autoantibodies. Haematological abnormalities of SLE include haemolytic anemia, leucopenia or lymphopenia, and thrombocytopenia, due to the production of autoantibodies [1]. Splenomegaly is not a common sign of SLE, unless there is concurrent infection.

On the other hand, visceral leishmaniasis is a chronic parasitic infection caused by Leishmania donovani. There is B-cell hyperactivity, resulting in production of autoantibodies such as ANA and others [2]. It is characterised by fever, cytopenias, and splenomegaly. Splenomegaly and hypersplenism are mainly responsible for cytopenias. Immunocompromised patients due to acquired immunodeficiency syndrome, after kidney-transplantation or leukemia are more commonly affected [3].

We report a case of SLE complicated by visceral leishmaniasis, with sharp clinical resemblance to a flare of SLE. A high suspicion for kala azar should always be kept when a patient comes from an endemic area of the disease with fever and splenomegaly, especially when superimposed on a background of an immunocompromised state.

2. Case Report

A 30-years-old female presented with complaints of low grade fever, multiple painful small joints with periarticular puffiness and bilateral pedal swelling for one month. She had history of distal phalangeal amputation 1 year back for bilateral upper limb digital infarcts. General examination revealed pallor and bilateral pitting pedal oedema. Palpable spleen 2 cm below subcostal margin was the only significant systemic finding.

Haematological investigations revealed haemoglobin 2.56 mmol/L, total leukocyte count 3.4 × 10^9/L, platelets 59 × 10^9/L and, albumin : globulin (A : G) ratio 2.0 : 5.6. Renal, liver, and thyroid function tests were normal. 24 hours urinary protein excretion was 581 mg. Antinuclear antibodies (ANA) and anti-double-stranded DNA (Anti dsDNA) antibodies were positive, titres being 7.3 and 6.8 times of upper limit of normal range. Antinuclear antibodies (ANA) and anti-double-stranded DNA (Anti dsDNA) antibodies were positive, titres being 7.3 and 6.8 times of upper limit of normal range. Anti-Ro, anti-La, and p-ANCA were also positive. Lupus anticoagulant (LA) and anticardiolipin antibody (ACLA) were negative. Renal biopsy was suggestive of lupus nephritis of mixed type.
Figure 1: Acid fuchsin or Masson’s trichome staining showing reddish coloured deposits on basement membrane.

Figure 2: Renal biopsy showing glomerular basement membrane thickening with mesangial proliferation.

Figure 3: Mononuclear cell infiltration with sclerosed, hyalinised glomeruli indicating chronic disease.

Figure 4: Giant mononuclear cells with pyknosis of nuclei indicating active disease process.

3. Discussion

Visceral leishmaniasis (VL) has already been reported with SLE [4, 5]. In such cases, it mimics a lupus flare [6]. IL-10 secreted by T-cells promotes B cell survival and plasma cell differentiation. Due to polyclonal activation of B cells, there is formation of several autoantibodies like ANA, and others [2]. Presence of ANA and anti-dsDNA can mislead the diagnosis of SLE in a patient of VL and immunosuppression, as a part of therapy of SLE can be detrimental in these patients. So development of fever, pancytopenia, and splenomegaly due to VL in a patient of SLE on immunosuppressive therapy can mimic disease flare which can lead to increase in dose of immunosuppressive therapy. In our patient fever, small joint pain, facial puffiness, past history of digital infarcts, pancytopenia, positivity of ANA, anti-dsDNA, proteinuria, and biopsy proven lupus nephritis lead to primary diagnosis of SLE. Initially, patient showed slight improvement on steroid therapy but gradual deterioration followed over next few months. Moreover, the derangement in laboratory parameters persisted after 1 year of therapy, along with massive splenomegaly. The suspicion for VL was so high that we went for DAT and PCR despite negative results in rK-39 test and bone marrow studies.
This was not the case with earlier reports in which VL was diagnosed easily with the latter tests. Therefore, we conclude that a high suspicion of kala-azar should always be kept in a patient of SLE, especially when he comes from an endemic area, and immunosuppressive therapy should be started only after ruling it out diligently.

**Authors’ Contributions**

All the authors have contributed equally in preparing this manuscript.

**Conflict of Interests**

There are no conflict of interests for any of the author in relation to this manuscript.

**Disclosure**

There is no role of any funding source in the writing of the manuscript of the decision to submit it for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**References**

[1] C. Mohan, S. Adams, V. Stanik, and S. K. Datta, “Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus,” *Journal of Experimental Medicine*, vol. 177, no. 5, pp. 1367–1381, 1993.

[2] E. Liberopoulos, G. Pappas, A. Kostoula, A. Drosos, E. Tsianos, and M. Elisaf, “Spectrum of autoimmunity and dysproteinemia in patients with visceral leishmaniasis,” *Clinical Microbiology and Infection*, vol. 9, supplement 1, p. 417, 2003.

[3] L. J. Martinez de Letona, C. M. Vazquez, R. P. Maestu et al., “Visceral leishmaniasis as an opportunistic infection,” *The Lancet*, vol. 1, no. 8489, p. 1094, 1986.

[4] B. Granell, J. Serratrice, L. Swiader et al., “Crossing of antinuclear antibodies and anti-leishmania antibodies,” *Lupus*, vol. 9, no. 7, pp. 548–550, 2000.

[5] P. V. Voulgaris, G. A. Pappas, E. N. Liberopoulos, M. Elisaf, F. N. Skopouli, and A. A. Drosos, “Visceral leishmaniasis resembling systemic lupus erythematosus,” *Annals of the Rheumatic Diseases*, vol. 63, no. 10, pp. 1348–1349, 2004.

[6] J. Braun, J. Sieper, K. L. Schulte, E. Thiel, and K. Janitschke, “Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus,” *Clinical Rheumatology*, vol. 10, no. 4, pp. 445–448, 1991.